Paper31623402
Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.
Kohl V and 10 others. Cancers (Basel), 2019. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. Papers, record 31623402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31623402
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| DJCLS 14 R/2017 | José Carreras Leukämie-Stiftung | PubMed |
Source PubMed
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 2 | 21941284 | A decade of exploring the cancer epigenome - biological and translational implications. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21941284 | PubMed |
| 3 | 22455312 | Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors. | J Med Chem | 2012 | https://conductscience.org/library/papers/22455312 | PubMed |
| 4 | 23786647 | Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. | Br J Haematol | 2013 | https://conductscience.org/library/papers/23786647 | PubMed |
| 5 | 23881923 | BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23881923 | PubMed |
| 6 | 23118055 | Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. | Cancer Res | 2012 | https://conductscience.org/library/papers/23118055 | PubMed |
| 7 | 21821475 | The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. | Mol Oncol | 2011 | https://conductscience.org/library/papers/21821475 | PubMed |
| 8 | 20348135 | Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/20348135 | PubMed |
| 9 | 19372272 | Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. | Nucleic Acids Res | 2009 | https://conductscience.org/library/papers/19372272 | PubMed |
| 10 | 22377908 | Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. | Int J Cancer | 2012 | https://conductscience.org/library/papers/22377908 | PubMed |
| 11 | 26594843 | Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. | Nat Med | 2015 | https://conductscience.org/library/papers/26594843 | PubMed |
| 12 | 16532500 | Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. | Cancer | 2006 | https://conductscience.org/library/papers/16532500 | PubMed |
| 13 | 29878489 | Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. | Am J Hematol | 2018 | https://conductscience.org/library/papers/29878489 | PubMed |
| 14 | 18626472 | Single-strand break repair and genetic disease. | Nat Rev Genet | 2008 | https://conductscience.org/library/papers/18626472 | PubMed |
| 15 | 25735917 | Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. | Leuk Res | 2015 | https://conductscience.org/library/papers/25735917 | PubMed |
| 16 | 19153658 | DNA repair in mammalian cells: Base excision repair: the long and short of it. | Cell Mol Life Sci | 2009 | https://conductscience.org/library/papers/19153658 | PubMed |
| 17 | 26529666 | Trypan Blue Exclusion Test of Cell Viability. | Curr Protoc Immunol | 2015 | https://conductscience.org/library/papers/26529666 | PubMed |
| 18 | 28588020 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. | Blood | 2017 | https://conductscience.org/library/papers/28588020 | PubMed |
| 19 | 24450632 | PARP inhibitors for anticancer therapy. | Biochem Soc Trans | 2014 | https://conductscience.org/library/papers/24450632 | PubMed |
| 20 | 17991682 | Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain length. | Nucleic Acids Res | 2007 | https://conductscience.org/library/papers/17991682 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41446759 | Contrasting roles of APE1 and APE2 in genome maintenance, cancer development, and therapeutic targeting. | NAR Cancer | 2025 | https://conductscience.org/library/papers/41446759 | PubMed |
| 41008918 | PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41008918 | PubMed |
| 39175540 | Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39175540 | PubMed |
| 35091444 | Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35091444 | PubMed |
| 35065680 | Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35065680 | PubMed |
| 34976824 | Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019. | Front Oncol | 2021 | https://conductscience.org/library/papers/34976824 | PubMed |
| 34703267 | New Horizons for the Roles and Association of APE1/Ref-1 and ABCA1 in Atherosclerosis. | J Inflamm Res | 2021 | https://conductscience.org/library/papers/34703267 | PubMed |
| 33868289 | Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868289 | PubMed |
| 33039802 | Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1. | DNA Repair (Amst) | 2020 | https://conductscience.org/library/papers/33039802 | PubMed |
| 33036275 | DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33036275 | PubMed |
| 32547565 | Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences. | Front Immunol | 2020 | https://conductscience.org/library/papers/32547565 | PubMed |
Genes44
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31623402
GET https://conductscience.org/api/papers/v1/31623402/references?page=2